Authors' recommendations: Description of Technology: Infliximab (IFX) (Remicade; Janssen Biotech Inc.) is a recombinant chimeric human-murine immunoglobulin G1 monoclonal antibody designed to target and block tumor necrosis factor-alpha (TNF-?) and, thereby, reduce inflammation and associated sequelae. For pediatric Crohn disease (CD), IFX is administered by intravenous infusion in an outpatient setting at weeks 0, 2, 6, and every 8 weeks thereafter. The role of IFX in pediatric CD primarily has been as a second-line, or step-up, approach after conventional CD drugs have failed. Suggested potential benefit from first-line IFX treatment for adult CD has led to the investigation of IFX as initial, or top-down, treatment for pediatric CD, with the goal of altering its natural history. Patient Population: IFX is a tumor necrosis factor blocker indicated for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients with moderately to severely active disease who have had an inadequate response to conventional therapy. IFX has not been studied in children aged < 6 years. Patient selection criteria have not been established for its use as first-line treatment for pediatric CD.

Project Status: Completed

Year Published: 2016

URL for published report: The report may be purchased from: http://www.hayesinc.com/hayes/crd/?crd=16117

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: United States

Organisation Name: HAYES, Inc.

Contact Address: 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218

Contact Name: saleinfo@hayesinc.com

Contact Email: saleinfo@hayesinc.com

Copyright: 2014 Winifred S. Hayes, Inc